pdufa.bio

Losartan

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET

Losartan is an Actuate Therapeutics, Inc. program. Its next catalyst is a Readout in Dec 2026. Every date links its source.

ACTU catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Actuate Therapeutics, Inc. (ACTU). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026ACTU

Questions

When is Losartan's next FDA decision or readout?

The next tracked catalyst for Losartan is a Readout in Dec 2026.

What happened at Losartan's most recent FDA decision?

No FDA decision for Losartan is in our archive yet.

Who makes Losartan?

Actuate Therapeutics, Inc. (ACTU).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.